市場概況

Biopsies are an important medical procedure where doctors extract cells or tissues from a patient’s body in order to examine them under a microscope. This closer inspection of samples provides critical information to help identify diseases and guide treatment decisions. By taking a small piece of suspect organs, tumors or lesions, pathologists can study the sampled cells and tissues at a microscopic level. This detailed evaluation allows them to discern abnormal cells and detect conditions that may otherwise go unnoticed. Examining samples directly reveals definitive answers about infection, cancer or other underlying issues in ways that routine blood tests simply cannot match.

The global biopsy devices market is poised for robust expansion between 2023 と 2029. The market is projected to grow at a compound annual growth rate of 8.3% over this period, adding over $2.2 billion in incremental value.

There are several drivers underpinning this positive outlook:
Rising incidence of cancer cases worldwide is directly increasing the number of biopsy procedures conducted each year. Biopsies provide a definitive tissue-based diagnosis that is essential for determining appropriate treatment plans. したがって, growth in cancer prevalence will propel biopsy device adoption in parallel.
Beyond cancer diagnosis, biopsies are routinely used to examine a wide array of health conditions spanning infections, kidney disorders, joint inflammation, skin diseases and others. This diverse scope of applications sustains constant demand among healthcare facilities.
Implementation of public awareness campaigns and screening programs aimed at early cancer detection are being rolled out globally. Subsidies and favorable reimbursement policies additionally improve biopsy access and affordability. These factors serve to further stimulate procedure volumes.

レポートは市場規模と成長をカバーしています, セグメンテーション, 地域内訳, 競争環境, trends and strategies for global biopsy devices market. 利害関係者が現在の市場機会を活用できるように、市場の定量的な分析を提供します。. このレポートはまた、市場動向と主要な競合他社のアプローチに基づいて、機会と戦略の上位セグメントを特定します。.

市場セグメンテーション

この業界レポートは、世界市場の市場推定と予測を提供します。, その後、製品の詳細な分析が行われます, biopsy type, guidance technique, anatomy, disease type, エンドユーザー, と地域.

By Product
Biopsy Devices
消耗品
サービス

By Biopsy Type
Tissue Biopsy
Liquid Biopsy

By Guidance Technique
Ultrasound-Guided Biopsy
Stereotactic Guided Biopsy
MRI-Guided Biopsy
CT Guided Biopsy
その他

By Disease Type
Cancer
Infections
Autoimmune Disorders
その他

By Anatomy
Abdominal Biopsy
Bone Biopsy
Breast Biopsy
Liver Biopsy
Lung Biopsy
Prostate Biopsy
Uterus/Cervix/Ovary Biopsy
その他

By End User
病院 & クリニック
Diagnostic & Imaging Centers
その他

地域別
北米
ヨーロッパ
アジア太平洋地域
世界のその他の地域

Analyzing product segments, liquid biopsy accounted for the largest revenue share in the global biopsy devices market in 2022. Liquid biopsies analyze blood samples to detect circulating cancer cells and DNA, enabling non-invasive diagnostics and monitoring. This emerging segment is forecast to see robust adoption growth given benefits like minimal invasiveness, repeat testing ability, and suitability for screening and companion diagnostics.

By anatomy, breast biopsies dominated global biopsy device utilization in 2022. This predominance is attributed to:
High Incidence – Breast cancer is the most prevalent cancer in women, driving biopsy demand for diagnosis.
Screening – Guidelines recommend regular mammogram screening for women above 40 または 50 based on risk factors. Further testing via biopsy is common.
監視 – Biopsies help track disease progression and treatment efficacy in breast cancer patients through the course of care.
Risk Assessment – Where mammograms and ultrasounds are inconclusive, breast biopsies provide definitive pathology results to determine benign or malignant growths and guide decisions.
Genomic Testing – Biopsies allow genomic characterization of breast tumors to select optimal personalized therapies.
Technological enhancements like vacuum-assisted systems, MRI-guided procedures and minimally invasive approaches have expanded breast biopsy capabilities while reducing patient discomfort.

地理的に, 北米が最大の収益シェアを占めた 2022, aided by high adoption of advanced biopsy systems, rising utilization, favorable reimbursements and easy accessibility. A developed healthcare infrastructure and focus on early cancer detection also advantage the region. Asia Pacific is expected to exhibit rapid growth fueled by improving healthcare access, growing diagnostics demand and rising cancer incidence. Though Europe represents a mature market, advancements in biopsy technology will support steady expansion.

主要企業と競争環境

The global biopsy devices market report offers detailed information on several market vendors, including Agilent Technologies, 株式会社, Argon Medical Devices, 株式会社, B. Braun Holding GmbH and Co. KG, ベクトン, ディキンソン アンド カンパニー, BGI Group Limited, バイオセプト, 株式会社, バイオ・ラッド研究所, 株式会社, ボストンサイエンティフィックコーポレーション, 枢機inalの健康, 株式会社, Conmed Corporation, Cook Group Incorporated, Dxcover Limited, Elypta AB, F. ホフマン・ラ・ロシュAG, 富士フイルムホールディングス株式会社, GE HealthCare Technologies, 株式会社, hologic, 株式会社, イルミナ, 株式会社, INRAD Inc., Integra Lifesciences Corporation, メドトロニック株式会社, Micronoma Inc., Ningbo Xinwell Medical Technology Co., 株式会社, オリンパス株式会社, キアゲン N.V., Revvity, 株式会社, シーメンス ヘルスニアーズ AG, Stryker Corporation, Sysmex Corporation, サーモフィッシャーサイエンティフィック株式会社, Zhejiang Kindly Medical Devices Co., 株式会社, とりわけ. このレポートでは, 市場の競争見通しを理解するために、主要なプレーヤーとその戦略を徹底的に分析します。.

報告書の範囲

To analyze and forecast the market size of the global biopsy devices market.
To classify and forecast the global biopsy devices market based on product, biopsy type, guidance technique, anatomy, disease type, エンドユーザー, 領域.
To identify drivers and challenges for the global biopsy devices market.
合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the global biopsy devices market.
To identify and analyze the profile of leading players operating in the global biopsy devices market.

このレポートを選択する理由

Gain a reliable outlook of the global biopsy devices market forecasts from 2023 に 2029 シナリオ全体にわたって.
投資対象となる成長セグメントを特定する.
会社概要と市場データを通じて競合他社に先んじる.
Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
3ヶ月間の戦略コンサルティングとリサーチサポート.
シングルユーザーライセンスに提供される印刷認証.